Sunao Manabe, Daiichi Sankyo CEO

Dai­ichi Sankyo scraps ear­ly-stage ADC pro­gram in gas­troin­testi­nal tu­mors af­ter first phase fail

Dri­ven by a se­ries of wins for its an­ti­body-drug con­ju­gate pipeline, Dai­ichi Sankyo has earned a rep­u­ta­tion as an ADC ex­pert with a suc­cess­ful part­ner­ship with As­traZeneca un­der its belt. But fail­ures do hap­pen — and for Dai­ichi, it’s where the com­pa­ny least ex­pect­ed it.

Dai­ichi has scrapped de­vel­op­ment of DS-6157, an ADC tar­get­ing the GPR20 pro­tein in gas­troin­testi­nal stro­mal tu­mors (GIST), af­ter the drug failed a Phase I test, the drug­mak­er re­vealed in its Q2 up­date Fri­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.